Isa-KRd Significantly Improves MRD Negativity Rates at Cutoffs Vs KRd in Newly Diagnosed Multiple Myeloma
Axatilimab Elicits Responses With Manageable Safety in Recurrent/Refractory cGVHD
Dr Bal on Updated Findings With BMS-986393 in Relapsed/Refractory Multiple Myeloma
Dr Ghia on a Biomarker Analysis of the SEQUOIA Trial in CLL/SLL
